STAT

APRIL 25, 2024

The need-to-know this morning AstraZeneca reported first-quarter  sales and profits  that topped analyst estimates, buoyed by its blockbuster cancer drugs. It’s a busy day for pharma earnings:  Merck ,  Sanofi ,  Daiichi Sankyo ,  Astellas , and  Bristol Myers Squibb.

Hospitals 280

Hospitals Drug Pricing 280

STAT

FEBRUARY 8, 2024

On Thursday, at a press briefing at which they presented their 2023 earnings, AstraZeneca executives also played coy about the bargaining over the price of the company’s diabetes drug Farxiga.  

Drug Pricing 311

Drug Pricing Diabetes 311

Express Pharma

MAY 12, 2024

Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year’s annual ‘Choose France’ business summit. Pfizer said it would invest 500 million euros ($538.5

89

89

PharmExec

JANUARY 9, 2023

The Anglo-Swedish drugmaker on Monday agreed to pay $26 per CinCor share in cash, or $1.3 billion in total, a premium of nearly 121% to the U.S.-based based company's closing price on Friday.

52

52

BioPharma Dive

NOVEMBER 20, 2023

Called Evinova, the unit will operate as a separate business within AstraZeneca, which sees digital health solutions as a market primed for growth.

116

116

Pharmaceutical Business Review

MAY 22, 2024

AstraZeneca CEO Pascal Soriot said: “Today AstraZeneca announces a new era of growth. The post AstraZeneca targets $80bn revenue by 2030 appeared first on Pharmaceutical Business review. The company’s ultimate goal is to reach science-based net zero by 2045. Its treatments are available in over 125 countries.

59

59

STAT

MARCH 19, 2024

Rise and shine, everyone, another busy day is on the way. … AstraZeneca agreed to acquire Fusion Pharmaceuticals in a deal worth more than $2 billion, picking up a company focused on the blooming area of targeted radiation therapies for cancer , STAT writes. Just keep scrolling down. And as always, do keep in touch.

285

285

The Guardian - Pharmaceutical Industry

MAY 21, 2024

UK’s biggest drugmaker says it plans to launch 20 major new medicines before the end of the decade Business live – latest updates Britain’s biggest drugmaker, AstraZeneca, has set out a bold ambition to reach $80bn (£63bn) in revenues by 2030 from treatments for cancer, rare diseases and other conditions, by launching 20 major new medicines before (..)

46

46

PharmExec

JUNE 13, 2022

Makar discusses the significance of AstraZeneca’s diabetes and heart failure drug Forxiga (dapagliflozin) for the treatment of chronic kidney disease (CKD).

Diabetes 98

Diabetes 98

The Guardian - Pharmaceutical Industry

DECEMBER 12, 2023

Britain’s biggest drugmaker acquires Seattle-based firm Icosavax, expanding vaccine and immune therapy business AstraZeneca is buying its first vaccine company in a $1.1bn deal that will expand the vaccine and immune therapy business it set up during the Covid-19 pandemic.

Vaccines 54

Vaccines Immunity Immunization 54

The Guardian - Pharmaceutical Industry

MARCH 19, 2024

Britain’s biggest drugmaker’s latest acquisition will help it to develop new radiotherapy treatments Business live – latest updates Britain’s biggest drugmaker, AstraZeneca, is to buy a Canadian cancer specialist focused on next-generation treatments for $2.4bn (£1.9bn), the latest in a string of acquisitions made to strengthen its portfolio of new (..)

Chemotherapy 59

Chemotherapy 59

STAT

NOVEMBER 8, 2023

And what better way to make the time fly than to keep busy. The companies that received warning notices included AbbVie, AstraZeneca, and subsidiaries of GSK and Teva Pharmaceutical. The middle of the week is upon us. Have heart, though. You made it this far, so why not hang on for another couple of days, yes?

Drug Pricing 249

Drug Pricing 249

LifeProNow

JULY 14, 2023

Enhertu is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialised by AstraZeneca and Daiichi Sankyo. This approval is an important advance in the way breast cancer is classified and treated in China and supports our vision to bring Enhertu to more patients worldwide.”

Chemotherapy 130

Chemotherapy Hospitals 130

Pharmaceutical Business Review

MARCH 19, 2024

The acquisition is a significant step in AstraZeneca’s strategy to transform cancer treatment by offering more targeted therapies as alternatives to traditional treatments like chemotherapy and radiotherapy. Under the acquisition terms, AstraZeneca will purchase all outstanding shares of Fusion for $21.00

Chemotherapy 59

Chemotherapy 59

Pharma Marketing Network

JULY 17, 2023

Jerry Valentine has over 15 years of pharmaceutical experience, including establishing relationships across marketing teams, agency partners, and extending business teams to implement multi-channel marketing programs for HCPs and consumers.

52

52

Big Molecule Watch

DECEMBER 26, 2023

announced the successful completion of the transition of the acquired biosimilars business in approximately 120 countries, a year ahead of schedule. On December 12, 2023, AstraZeneca announced it has agreed to acquire Icosavax, Inc., The post Biosimilar Deals Updates: Biocon, AstraZeneca appeared first on Big Molecule Watch.

Biosimilars 62

Biosimilars Vaccines Hospitals 62

Pharmaceutical Technology

AUGUST 8, 2022

AstraZeneca and Daiichi Sankyo ’s Enhertu (trastuzumab deruxtecan) has received expanded approval from the US Food and Drug Administration (FDA) to treat adults with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer.

Chemotherapy 105

Chemotherapy Labelling 105

Pharmaceutical Technology

SEPTEMBER 9, 2022

US-based biotech company Gatehouse Bio is extending its collaboration with AstraZeneca for developing RNA therapeutics to treat heart failure with preserved ejection fraction (HFpEF). The post Gatehouse Bio and AstraZeneca to develop RNA therapeutics for heart failure appeared first on Pharmaceutical Technology.

Compounding 98

Compounding 98

European Pharmaceutical Review

FEBRUARY 22, 2023

European Pharmaceutical Review recently spoke to Miriam Guest, Principal Microbiologist at AstraZeneca UK, who has been involved in work to establish a short-, mid- and long-term strategy to optimise BET across the global business.

94

94

STAT

JULY 6, 2023

As for us, we are busy with the usual sorts of things. The petitioners are 21 companies from five corporate families — AstraZeneca, GE Healthcare Technologies, Johnson & Johnson, Pfizer. The business comprises more than 400 APIs used in drugs to treat everything from migraines to diabetes, and employs over 5,000 staff.

Drug Pricing 232

Drug Pricing Vaccines Diabetes Pharmaceutical Companies 232

European Pharmaceutical Review

FEBRUARY 22, 2023

AstraZeneca’s tablet formulation of Calquence (acalabrutinib) has been approved in the European Union (EU) for adults with chronic lymphocytic leukaemia (CLL). According to AstraZeneca, in B cells, BTK signalling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis and adhesion.

82

82

Pharmaceutical Technology

JANUARY 27, 2023

The European Union (EU) has granted approval for Daiichi Sankyo and AstraZeneca ’s Enhertu (trastuzumab deruxtecan) as monotherapy to treat unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-) breast cancer adult patients. It has been developed using the DXd ADC technology from Daiichi Sankyo.

Chemotherapy 94

Chemotherapy 94

Pharmaceutical Technology

AUGUST 12, 2022

The US Food and Drug Administration (FDA) has granted approval for Daiichi Sankyo and AstraZeneca ’s Enhertu (fam-trastuzumab deruxtecan-nxki) to treat unresectable or metastatic non-small cell lung cancer (NSCLC) in adults.

Chemotherapy 105

Chemotherapy 105

STAT

MARCH 26, 2024

Rise and shine, everyone, another busy day is on the way. In its lawsuit, the company argued the mandate for the state prescription drug affordability board is unconstitutional because its actions will conflict with federal law, violate basic requirements of due process, and seek to regulate business outside of Colorado.

Drug Pricing 262

Drug Pricing Insurance Coverage and Processing Diabetes Pharmaceutical Companies 262

Pharmaceutical Technology

DECEMBER 19, 2022

Business Expansion. Business Expansion is one of our largest categories and looks at the core functions of business operations within the sector. AstraZeneca/Daiichi Sankyo Nokia Bell Labs andEquideum Health Oak Hill Bio. AbbVie AstraZeneca Eli Lilly/Boehringer Fennec Moderna Novartis Pfizer Sanofi Teoxane.

52

52

Drug Patent Watch

MAY 23, 2021

ZOMIG (zolmitriptan) Astrazeneca Patent: 7,220,767 Expiration: May 28, 2021 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit….

69

69

Drug Patent Watch

MARCH 2, 2022

BYDUREON PEN (exenatide synthetic) Astrazeneca ab Patent: 7,223,440 Expiration: Mar 3, 2022 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact….

52

52

European Pharmaceutical Review

MARCH 7, 2024

AstraZeneca to boost cell therapy operations with $300m manufacturing investment Advancing the UK’s life sciences sector The Chancellor also confirmed that companies will soon be able to apply for a share of the £520 million funding for life sciences manufacturing announced at Autumn Statement.

Pharmaceutical Companies 96

Pharmaceutical Companies Pharmaceutical Companies Packaging Vaccines 96

Pharmaceutical Business Review

AUGUST 7, 2023

In the end of March next year, it is claimed to complete its business as a corporate entity. Enhertu is specifically engineered HER2-directed antibody drug conjugate (ADC) and is jointly developed and marketed by Daiichi Sankyo together with AstraZeneca. The companies signed a global collaboration agreement in March 2019 for Enhertuu.

52

52

pharmaphorum

JULY 14, 2022

Bayer’s venerable testosterone replacement product for men with hypogonadism – Nebido – is being sold to Grünenthal as the group continues a revamp of its healthcare business. It will also take ownership of a contract business in the US, where Endo Pharmaceuticals licenses Nebido from Bayer and sells it under the Aveed brand name.

Diabetes 97

Diabetes 97

pharmaphorum

SEPTEMBER 1, 2022

AstraZeneca has succeeded in a last-gasp effort to stop its former head of investor relations joining rival UK pharma group GSK, after winning an injunction in the High Court in London. ” It’s not the first time that AZ has taken legal action to try to prevent one of its former executives making the move to its rival.

104

104

pharmaphorum

MAY 7, 2021

She will oversee the strategy for several clients, and she’ll manage a team that works across all business units in order to ensure The Bloc’s competitive differentiation is present for each client. Antoinette earned a BS from Georgetown University and an MBA from the Fordham University Graduate School of Business in New York City.

Diabetes 98

Diabetes Vaccines 98

Express Pharma

MAY 14, 2024

Alison Labya, Business Fundamentals Analyst at GlobalData, comments: “The recent upturn in biopharmaceutical M&A signals a return in dealmaking confidence, as big pharma companies also look to mitigate the challenges such as the Inflation Reduction Act and upcoming patent expirations.”

Pharmaceutical Companies 90

Pharmaceutical Companies Pharmaceutical Companies 90

LifeProNow

MARCH 24, 2023

Dave Fredrickson, Executive Vice President, Oncology Business Unit, AstraZeneca, said: “This approval for Calquence offers people living with mantle cell lymphoma in China an effective and tolerable new treatment option to help control their disease.

Hospitals 130

Hospitals 130

Pharmaceutical Technology

DECEMBER 29, 2022

The Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved AstraZeneca ’s immunotherapies Imfinzi (durvalumab) and Imjudo (tremelimumab) to treat advanced liver, biliary tract, and lung cancers. The combination of Imfinzi and Imjudo has been approved to treat unresectable hepatocellular carcinoma (HCC) in adult patients.

Chemotherapy 52

Chemotherapy 52

pharmaphorum

SEPTEMBER 18, 2020

AstraZeneca is a company with a turbulent history but, for now, a promising future. In 1998, Europe’s corporate landscape was riding a “merger wave” – intensive competitive pressure meant that opportunities arose for companies to merge with their competitors in order to rationalise both businesses. Zeneca Group plc.

Vaccines 115

Vaccines Pharmaceutical Companies Pharmaceutical Companies Drug Development 115

pharmaphorum

DECEMBER 1, 2020

AstraZeneca is to sell European rights to its cholesterol drug Crestor (rosuvastatin) to Germany’s Grunenthal. AstraZeneca will also continue selling the medicine in other countries, including those in North America, Japan, China and other emerging markets.

82

82